Thyroid Hormone and Mitochondrial Dysfunction: Therapeutic Implications for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Cells · 09.12.2023 · 12 (24) · 2806
DOI: 10.3390/cells12242806 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 09.12.2023. Verfasst von Raghu Ramanathan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, University of Missouri, Columbia, MO 65212, USA. Hauptthemen laut MEDLINE: Metabolic Diseases, Non-alcoholic Fatty Liver Disease, Mitochondrial Diseases. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, CSRD VA, Veterans Administration Merit Review.
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly termed nonalcoholic fatty liver disease (NAFLD), is a widespread global health concern that affects around 25% of the global population. Its influence is expanding, and it is anticipated to overtake alcohol as the leading cause of liver failure and liver-related death worldwide. Unfortunately, there are no approved therapies for MASLD; as such, national and international regulatory health agencies undertook strategies and action plans designed to expedite the development of drugs for treatment of MASLD. A sedentary lifestyle and an unhealthy diet intake are important risk factors. Western countries have a greater estimated prevalence of MASLD partly due to lifestyle habits. Mitochondrial dysfunction is strongly linked to the development of MASLD. Further, it has been speculated that mitophagy, a type of mitochondrial quality control, may be impaired in MASLD. Thyroid hormone (TH) coordinates signals from the nuclear and mitochondrial genomes to control mitochondrial biogenesis and function in hepatocytes. Mitochondria are known TH targets, and preclinical and clinical studies suggest that TH, thyroid receptor β (TR-β) analogs, and synthetic analogs specific to the liver could be of therapeutic benefit in treating MASLD. In this review, we highlight how mitochondrial dysfunction contributes to development of MASLD, and how understanding the role of TH in improving mitochondrial function paved the way for innovative drug development programs of TH-based therapies targeting MASLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, University of Missouri, Columbia, MO 65212, USA.
- Harry S. Truman Memorial Veterans Medical Center, University of Missouri, Columbia, MO 65212, USA.
- Department of Medical Pharmacology and Physiology, University of Missouri, Columbia, MO 65212, USA.
ORCID-Profile: Raghu Ramanathan, Ahmad Hassan Ali, Jamal A Ibdah
Förderung
- BLRD VA
- CSRD VA
- Veterans Administration Merit Review
Zitieren
APA
Ramanathan, R., Patwa, S. A., Ali, A. H., & Ibdah, J. A. (2023). Thyroid Hormone and Mitochondrial Dysfunction: Therapeutic Implications for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Cells, 12(24), 2806. https://doi.org/10.3390/cells12242806
Vancouver
Ramanathan R, Patwa SA, Ali AH, Ibdah JA. Thyroid Hormone and Mitochondrial Dysfunction: Therapeutic Implications for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Cells. 2023;12(24):2806. doi:10.3390/cells12242806
BibTeX
@article{Ramanathan2023,
author = {Ramanathan, Raghu and Patwa, Sohum A and Ali, Ahmad Hassan and Ibdah, Jamal A},
title = {Thyroid Hormone and Mitochondrial Dysfunction: Therapeutic Implications for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)},
journal = {Cells},
year = {2023},
volume = {12},
number = {24},
pages = {2806},
doi = {10.3390/cells12242806}
}
EUVIMED